Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

Norwegian Cruise Line Holdings’ consensus analyst price target has recently shifted, decreasing from $31.12 to $29.74. Market observers are factoring in the company’s evolving risk profile and growth ...

FrontView REIT (NYSE: FVR) is set to give its latest quarterly earnings report on Wednesday, 2025-11-12. Here's what ...

Nvidia's partnership is key to this company's future growth. Operating-profit growth is expected to accelerate in the future ...

Debt Management: Castle Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.08, the company relies less on debt financing, maintaining a healthier balance between debt ...

Q3 2025 Management View CEO Douglas Francis reported that third quarter revenue was in line with guidance, but emphasized ongoing challenges: “several key markets continue to feel the impact from ...

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and ...

The 2025 NFL season hasn't started yet, but the Los Angeles Rams' most dire roster needs likely won't be resolved by the end of the year unless they make another major trade. The are of main concern ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated diseases, today announced compelling safety ...